Abiomed, Inc.
ABMD · NASDAQ
3/31/2022 | 3/31/2021 | 3/31/2020 | 3/31/2019 | |
|---|---|---|---|---|
| Market Cap | $15,053,202 | $14,387,472 | $6,558,184 | $12,474,479 |
| - Cash | $132,818 | $232,710 | $192,341 | $121,021 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $14,920,384 | $14,154,762 | $6,365,843 | $12,353,458 |
| Revenue | $1,031,753 | $847,522 | $840,883 | $769,432 |
| % Growth | 21.7% | 0.8% | 9.3% | – |
| Gross Profit | $843,595 | $685,615 | $689,578 | $639,865 |
| % Margin | 81.8% | 80.9% | 82% | 83.2% |
| EBITDA | $500,461 | $246,937 | $257,482 | $230,767 |
| % Margin | 48.5% | 29.1% | 30.6% | 30% |
| Net Income | $136,505 | $225,525 | $203,009 | $259,016 |
| % Margin | 13.2% | 26.6% | 24.1% | 33.7% |
| EPS Diluted | 2.98 | 4.94 | 4.43 | 5.61 |
| % Growth | -39.7% | 11.5% | -21% | – |
| Operating Cash Flow | $285,390 | $274,578 | $314,920 | $252,197 |
| Capital Expenditures | -$35,763 | -$53,383 | -$44,006 | -$44,004 |
| Free Cash Flow | $249,627 | $221,195 | $270,914 | $208,193 |